Education
About Us
Working with TipRanks
Follow Us
Neuphoria Therapeutics (NEUP)
NASDAQ:NEUP
Total Valuation
Neuphoria Therapeutics has a market cap or net worth of $36.59M. The enterprise value is ―.
Market Cap$36.59M
Enterprise Value―
Share Statistics
Neuphoria Therapeutics has 2,357,613 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,357,613
Owned by Insiders―
Owned by Institutions6.93%
Financial Efficiency
Neuphoria Therapeutics’s return on equity (ROE) is -0.02 and return on invested capital (ROIC) is -2.03%.
Return on Equity (ROE)-0.02
Return on Assets (ROA)-0.01
Return on Invested Capital (ROIC)-2.03%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee0.00
Profits Per Employee-46.20M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Neuphoria Therapeutics is ―. Neuphoria Therapeutics’s PEG ratio is -0.24.
PE Ratio―
PS Ratio0.00
PB Ratio0.61
Price to Fair Value0.61
Price to FCF149.20
Price to Operating Cash Flow11.22K
PEG Ratio-0.24
Income Statement
In the last 12 months, Neuphoria Therapeutics had revenue of 0.00 and earned -369.63M in profits. Earnings per share was -0.23.
Revenue0.00
Gross Profit0.00
Operating Income-1.13B
Pretax Income-838.00M
Net Income-369.63M
EBITDA-1.13B
Earnings Per Share (EPS)-0.23
Cash Flow
In the last 12 months, operating cash flow was 3.43M and capital expenditures 0.00, giving a free cash flow of 3.43M billion.
Operating Cash Flow3.43M
Free Cash Flow3.43M
Free Cash Flow per Share1.45
Dividends & Yields
Neuphoria Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.78
52-Week Price Change-6.25%
50-Day Moving Average12.12
200-Day Moving Average7.38
Relative Strength Index (RSI)27.24
Average Volume (3m)89.21K
Important Dates
Neuphoria Therapeutics upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Neuphoria Therapeutics as a current ratio of 3.56, with Debt / Equity ratio of 0.66%
Current Ratio3.56
Quick Ratio3.56
Debt to Market Cap0.01
Net Debt to EBITDA12.48
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Neuphoria Therapeutics has paid -468.37M in taxes.
Income Tax-468.37M
Effective Tax Rate0.56
Enterprise Valuation
Neuphoria Therapeutics EV to EBITDA ratio is 2.28, with an EV/FCF ratio of -33.30.
EV to Sales0.00
EV to EBITDA2.28
EV to Free Cash Flow-33.30
EV to Operating Cash Flow-33.30
Balance Sheet
Neuphoria Therapeutics has $17.05M in cash and marketable securities with $172.46K in debt, giving a net cash position of $16.87M billion.
Cash & Marketable Securities$17.05M
Total Debt$172.46K
Net Cash$16.87M
Net Cash Per Share$7.16
Tangible Book Value Per Share$3.43
Margins
Gross margin is 96.83%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin96.83%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Neuphoria Therapeutics is $19.43, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$19.43
Price Target Upside351.86% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast―